Capital and Business Alliances and Business Succession in Growth Areas

「東邦HDは「成長戦略実現の為の様々な施策の一つとしてPHCHDの買収に関する検討を行っていたが、このたび本件に関する検討を終了した」とし、「今後も、中期経営計画に掲げる経営目標の達成、中長期的な企業価値の向上に向け、最適な成長戦略を検討・推進する」とのコメントを発表した。」

「このたび本件に関する検討を終了することといたしましたので、お知らせいたします。」

「At a meeting of the Board of Directors held on 3 June 2026, the company resolved to sell all shares of its equity-method affiliate, あゆみ製薬ホールディングス株式会社.」

「In July, Teijin Regene株式会社 and Itochu Corporation entered into a business alliance, and the 3 companies began building a 「Regenerative Medicine Ecosystem」 to provide one-stop support for the services required to launch regenerative medicine products. As a first step, in September the 3 companies jointly held a 「Regenerative Medicine Top Runner Seminar」 for pharmaceutical manufacturers and drug-discovery ventures.」

「Regarding growth investment and efforts to improve profitability, the company entered into a capital and business alliance with ワコン株式会社, which manufactures and sells logistics equipment, including constant-temperature containers for pharmaceuticals, in anticipation of the growth of specialty products as the mainstream of the future pharmaceutical market. By jointly developing new constant-temperature transport products for specialty products requiring strict temperature and quality control, and developing new applications for the company's existing transport products, the company will further strengthen its temperature-controlled logistics system for maintaining product quality even amid abnormal weather conditions in recent years, such as rising temperatures.」

「To begin handling regenerative medicine products, whose market is expected to grow, and establish a framework for proper distribution, the company newly established the Regenerative Medicine Management Office within 東邦薬品株式会社.」

「With MICIN, with which the company entered into a capital and business alliance in September 2023, both companies established a project team comprising 6 subcommittees and began considering specific areas of collaboration.」

「In September this year, the company entered into a capital and business alliance with MICIN, Inc., which operates online medical services and digital solutions for clinical development. The company expects synergies between MICIN's businesses and its own pharmaceutical wholesale, dispensing pharmacy and customer support system businesses, among others, and believes the alliance will help address various challenges in healthcare and contribute to enhancing corporate value over the medium to long term.」

「In April this year, the company also established a collaborative research laboratory with the National Institute of Advanced Industrial Science and Technology (AIST). Eight seconded researchers and 16 in-house researchers from the group are participating in joint research aimed at addressing challenges in access to healthcare and implementing new technologies, systems and services in society.」

「As one of its medium- to long-term management strategies, the company is incorporating cutting-edge technologies in growth fields, promoting unconstrained collaboration and making active investments. As part of these efforts, it agreed to establish a collaborative research laboratory with the National Institute of Advanced Industrial Science and Technology (AIST) from April 2023 and conduct joint research to address various challenges in access to healthcare.」

「Together with Sysmex Corporation, we also began an initiative to provide dry-ice-free transport using the constant-temperature transport device 「サルム」 for the supply of quality-control materials requiring advanced refrigerated transport.」

「In response to the increase in pharmaceuticals, including vaccines for COVID-19, that require strict temperature control during refrigerated transport, we newly developed the constant-temperature transport device 「サルム FZ」, which supports transport across a wide temperature range from −25°C to +4°C.」

「In March 2022, we acquired part of the shares of AYM HD株式会社, which owns all shares of あゆみ製薬株式会社, a specialty pharmaceutical company in rheumatology and orthopedics that develops and introduces biologics and biosimilars.」

「We are also working to build new revenue models by investing management resources in growth fields such as regenerative medicine products, biopharmaceuticals and gene therapy pharmaceuticals. As part of these efforts, we invested in セルジェンテック株式会社, which is developing gene therapy cell products using adipose cells jointly with Chiba University, and セルージョン株式会社, a regenerative medicine venture originating at the School of Medicine of Keio University that is developing a new treatment for bullous keratopathy using corneal endothelial replacement cells derived from iPS cells.」

「We also worked to strengthen our business foundation, including by deciding that 東邦薬品株式会社 would succeed to the pharmaceutical sales business operated by 神戸医師協同組合.」

「As measures to improve profitability over the medium term, we entered into a capital and business alliance with モリモト医薬グループ, which has innovative lyophilization technology, and invested in growth fields by succeeding to the constant-temperature transport equipment business from 富士フイルム富山化学株式会社, among other initiatives.」